Therefore, considering the supporting data from the literature, we hypothesized that the heterogeneity linked to the tumor infiltration by immune cells with anti-cancer activities could explain the observed correlation between a higher phenotypic ITH and a better outcome in a group of patients with HER2-positive breast cancers. The gene discussed is ERBB2; the disease is neoplasm.